Skip to content
Peptide research

Crystagen

Also known as Immune Bioregulator
Category
Bioregulators
Administration routes
Oral
Regulatory status
Not FDA-approved

What it is

Crystagen is a synthetic tripeptide (Glu-Asp-Pro) marketed to normalize immune function, boost stress resistance, and support thymus activity during aging. The case is mechanism only: effects on T-cell gene expression are unconfirmed in humans, so claimed benefits remain speculative. Independent safety data are limited, with a theoretical risk of worsening autoimmune conditions. It is not FDA-approved and circulates as unregulated research-grade product.

Read Full record

Studied uses & evidence

Studied uses(3)

  • Immune system normalization and support

    Speculative

    Developer reports include laboratory studies and a small clinical comparison; independent clinical benefit remains unconfirmed.

  • Increased stress resistance in athletes

    Speculative

    Developer reports describe combination use in athletes; they do not establish a Crystagen-specific benefit.

  • Support for thymus function during aging (immunosenescence)

    Speculative

    Developer patent experiments include thymus models; clinical thymus rejuvenation remains unproven.

Evidence limits

Evidence Level
Very Limited Evidence

Direct clinical evidence for Crystagen is very limited. The strongest supporting data comes from the broader thymus peptide research (thymalin, thymogen) conducted in Russia over several decades, which shows immunocorrective effects. Crystagen specifically has been used in multi-peptide regimens for athletes but lacks standalone randomized controlled trials. The PMC-indexed thymalin review provides mechanistic context but not direct Crystagen clinical evidence.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Risk summary(2)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Limited independent safety data

    High
  • Potential immune modulation in autoimmune conditions

    Theoretical
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.